SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis > Premier Biomedical Inc (BIEI)

Premier Biomedical, Inc. is a biomedical company traded

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
dranesthesia1 Member Profile
Member Level 
Followed By 181
Posts 20,341
Boards Moderated 3
Alias Born 08/26/15
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/5/2017 6:05:53 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/21/2017 6:05:02 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 11/15/2017 6:06:47 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 10/27/2017 6:01:48 AM
Securities Registration Statement (s-1/a) "Edgar (US Regulatory)" - 10/16/2017 5:32:24 PM
Securities Registration Statement (s-1/a) "Edgar (US Regulatory)" - 10/4/2017 5:31:13 PM
MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing "InvestorsHub NewsWire" - 8/30/2017 10:29:33 PM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 8/30/2017 5:33:05 PM
PotNetwork Holdings, Inc Confirmed for MJAC 2017 "InvestorsHub NewsWire" - 8/28/2017 10:43:55 AM
MJAC 2017 International Cannabis Conference - Discount Code "InvestorsHub NewsWire" - 8/25/2017 6:50:56 PM
Book your ticket now for InvestorsHubs International Cannabis Conference "InvestorsHub NewsWire" - 8/23/2017 12:50:25 PM
MJAC 2017 - Speaker Update - Investing In The U.S. Cannabis Market "InvestorsHub NewsWire" - 8/22/2017 1:27:13 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/21/2017 5:12:40 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 8/14/2017 5:12:52 PM
Withdrawal of Registration Statement (rw) "Edgar (US Regulatory)" - 7/24/2017 6:03:46 AM
Premier Biomedical, Inc. CEO Letter - July, 2017 "InvestorsHub NewsWire" - 7/17/2017 7:00:00 AM
Premier Biomedical Integrates CBD-Based Pain Relief Products Business; Expands Current and New Product Offerings "InvestorsHub NewsWire" - 7/13/2017 10:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/12/2017 6:12:45 AM
Securities Registration Statement (s-1/a) "Edgar (US Regulatory)" - 7/6/2017 12:57:38 PM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 5/26/2017 6:06:30 AM
Withdrawal of Registration Statement (rw) "Edgar (US Regulatory)" - 5/23/2017 5:24:32 PM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 5/23/2017 5:24:06 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/22/2017 5:17:27 PM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 5/18/2017 4:31:58 PM
dranesthesia1 Member Level  Sunday, 02/19/17 05:38:41 PM
Re: None
Post # of 49690 
Premier Biomedical, Inc. is a biomedical company traded in on the OTCQB under ticker BIEI. The company began a joint venture late last year and opened a new division Premier Biomedical Pain Management Solutions (PBPMS) to manufacture and distribute pain relief products.

Historically, the company has not had a revenue stream. BIEI has several key patents pending. The most notable patent is for a cancer treatment, which outperformed other leading cancer treatments in laboratory testing. The next test of this treatment will be on humanized mice. Due to the cost of testing, the company wanted to sell oral pain relief treatments to generate revenue. The FDA testing for an oral treatment would cost upwards of a million dollars and a year or two in time. The company decided to change to topical treatments, which do not require FDA approval.

The company did have a burn rate of $100,000 a month and had a settlement of $300,000, causing dilution of stock. The current OS is approximately 400,000,000.

The products sold currently by PBPMS are a 96-hour patch and roll-on CBD oil. The patch has CBD and other natural ingredients. These products appear to be better than competing brands. Other products will be available later.

The P/Es are not available yet for PBPMS since the website launched less than one month ago. The number of orders generated so far is approximately 400. No average order dollar amount is available. The company has agreements with wellness centers and a small retail chain for product distribution. More points of sale agreements are expected.

The CEO, William Hartman, has had several recent interviews that provide considerable information. Look for Uptick interviews.

What should investors expect?
Dilution should end soon.
With the absence of dilution, the stock price per share should increase to reflect a realistic market cap.
Sales of products should increase, since reviews are very positive and points of sale will increase.

Last 10Q: http://www.discountedgar.com/data/biei/filesUploaded/biei10q033116.pdf
Company website: http://www.premierbiomedical.com/
PBPMS website: http://painreliefmeds.com/
Uptick: https://upticknewswire.com/tag/biei/
Facebook: https://www.facebook.com/Bieiotc/
Twitter: @bieiotc #pain #painreliefmeds


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist